How common is the non-nucleoside reverse transcriptase inhibitor mutation E138K in clinical practice?

Journal of Infection

Volumn 63, Issue 2, 2011, Pages 172-173

  Bradshaw, Daniel ^a   Mandalia, Sundhiya ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CLADISTICS; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; LETTER; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPIC VARIATION; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS;

EID: 79960890917     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.06.003     Document Type: Letter

References (9)

1. Bhattacharya S., Osman H. Novel targets for anti-retroviral therapy. J Infect 2009, 59:377-386. 10.1016/j.jinf.2009.09.014.
2. Pozniak A.L., Morales-Ramirez J., Katabira E., Steyn D., Lupo S., Santoscoy M., et al. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 individuals: week 96 results of a phase IIb randomized trial. AIDS 2010, 24:55-65.
3. Asahchop E.L., Oliveira M., Wainberg M.A., Brenner B.G., Moisi D., d'Aquin Toni T., et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011, 55:600-607.
4. Asahchop E, Tremblay C, Brenner B, Oliveira M, Moisi D, Toni T et al. Selection in vitro of a novel etravirine associated resistance mutation in B and non-B HIV-1 subtypes. 17th CROI Poster 552 2010.
5. Brillant JE, Klumpp K, Swallow S, Mirzadegan T, Cammack N, Heilek-Snyder G. In vitro resistance development for a second generation NNRTI: TMC125. XIII International HIV Drug Resistance Workshop. Poster 16 2004.
6. Su G, Li Yu, Paul A, Hang J, Harris S, Hogg H et al. In vitro selection and characterization of viruses resistant to R1206, a novel nonnucleoside reverse transcriptase inhibitor. XVI International HIV Drug Resistance Worskhop. Poster 33 2007.
7. Gatanaga H., Ode H., Hachiya A., Hayashida T., Sato H., Takiguchi M., et al. Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. AIDS 2010, 24:F15-F22.
8. Ren J., Nichols C.E., Stamp A., Chamberlain P.P., Ferris R., Weaver K.L., et al. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J 2006, 273:3850-3860.
9. Stanford University HIV Drug Resistance Database.